BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Injectafer / Ferinject (Ferric carboxymaltose) readouts · Ass
 etMemo
X-WR-CALDESC:Upcoming readouts of Injectafer / Ferinject (Ferric carboxymal
 tose)\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05226169-590@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 3 readout est
 . (NCT05226169)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 3.\nStud
 y: Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced 
 Gastric Cancer(EFFECT-AGC)\nEstimated primary completion: 30 November 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ferric-carboxymalto
 se#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5226169
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05793996-590@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 4 readout est
 . (NCT05793996)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 4\, Hear
 t Failure.\nStudy: The Prevalence of Iron Deficiency and the Effectiveness
  of Ferinject® in Patients With HFpEF (ID-HFpEF)\nEstimated primary compl
 etion: December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ferric-carboxymaltose#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05793996
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05759078-590@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 4 readout est
 . (NCT05759078)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 4.\nStud
 y: Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascu
 lar Morbidity\, and Quality of Life in Iron Deficient Patients With Recent
  Myocardial infarCTion\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ferric-carboxymaltose#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05759
 078
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217873-590@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 2/3 readout e
 st. (NCT07217873)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 2/3.\nSt
 udy: IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study\nEs
 timated primary completion: 31 August 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07217873
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06061393-590@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 4 readout est
 . (NCT06061393)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 4\, Iron
  Deficiency Anemia.\nStudy: Comparison Between Outcomes of Pregnant Women 
 Treated With Ferinject vs. Venofer for Iron Deficiency Anemia\nEstimated p
 rimary completion: September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ferric-carboxymaltose#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06061393
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772453-590@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 4 readout est
 . (NCT07772453)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 4\, Iron
  Deficiency Anemia.\nStudy: Ferric Carboxymaltose Versus Iron Sucrose for 
 Iron Deficiency Anemia After Radical Gastrectomy for Gastric Cancer\nEstim
 ated primary completion: November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07772453
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05744219-590@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 3 readout est
 . (NCT05744219)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 3.\nStud
 y: Improved Recovery by Iron Following Surgery With Blood Loss\, the IRIS-
 trial\nEstimated primary completion: 31 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05744219
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07721519-590@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase na readout es
 t. (NCT07721519)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase na\, Iro
 n Deficiency Anemia.\nStudy: Comparing Two Intravenous Iron Treatments for
  Anemia in Kurdish Pregnant Women\nEstimated primary completion: 1 March 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ferric-carboxyma
 ltose#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07721519
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07476859-590@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 4 readout est
 . (NCT07476859)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 4.\nStud
 y: Effect of Intravenous Iron on Quality of Life in Older Patients With Ac
 ute Coronary Syndrome\nEstimated primary completion: April 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07476859
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06833788-590@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20280622
DTEND;VALUE=DATE:20280623
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 4 readout est
 . (NCT06833788)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 4.\nStud
 y: Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron 
 and Postpartum Depression\nEstimated primary completion: 22 June 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ferric-carboxymaltose#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068337
 88
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07370688-590@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 4 readout est
 . (NCT07370688)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 4.\nStud
 y: Iron Infusion in Patients Undergoing Transcatheter Aortic Valve Implant
 ation\nEstimated primary completion: July 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07370688
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07359599-590@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 4 readout est
 . (NCT07359599)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 4.\nStud
 y: The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmo
 nary Hypertension\nEstimated primary completion: July 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07359599
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07822607-590@assetmemo.bio
DTSTAMP:20261121T005000Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Injectafer / Ferinject (Ferric carboxymaltose): Phase 2 readout est
 . (NCT07822607)
DESCRIPTION:Injectafer / Ferinject (Ferric carboxymaltose)\, phase 2.\nStud
 y: Intravenous Iron in the Management of Drug-resistant Restless Legs synd
 romeI\nEstimated primary completion: April 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07822607
URL:https://assetmemo.bio/drug/ferric-carboxymaltose#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
